Zacks Research Issues Optimistic Outlook for Amarin Earnings

Amarin Co. plc (NASDAQ:AMRN) – Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for shares of Amarin in a research note issued on Wednesday, May 28th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($0.87) for the quarter, up from their previous forecast of ($1.12). The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.81) EPS, FY2025 earnings at ($3.74) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($3.21) EPS, Q1 2027 earnings at ($0.32) EPS and FY2027 earnings at ($2.52) EPS.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%.

AMRN has been the subject of a number of other research reports. Wall Street Zen upgraded Amarin from a “sell” rating to a “hold” rating in a report on Thursday, May 8th. The Goldman Sachs Group reduced their price target on Amarin from $20.00 to $7.00 and set a “sell” rating for the company in a report on Thursday, April 17th.

Amarin Stock Performance

Amarin stock opened at $11.60 on Friday. Amarin has a 52 week low of $7.08 and a 52 week high of $17.58. The stock has a market capitalization of $240.20 million, a P/E ratio of -128.89 and a beta of 0.66. The stock has a 50-day simple moving average of $10.02 and a 200 day simple moving average of $10.22.

Institutional Investors Weigh In On Amarin

Hedge funds have recently bought and sold shares of the stock. Banque Cantonale Vaudoise acquired a new stake in Amarin during the first quarter worth approximately $25,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Amarin in the fourth quarter valued at approximately $36,000. Kornitzer Capital Management Inc. KS raised its position in shares of Amarin by 4.0% in the first quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 3,400 shares in the last quarter. Generation Capital Management LLC acquired a new stake in shares of Amarin in the fourth quarter valued at approximately $50,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Amarin in the fourth quarter valued at approximately $55,000. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.